Alto Neuroscience has achieved a significant milestone with the FDA granting Fast Track designation for ALTO-101, targeting cognitive impairment associated with schizophrenia. This designation underscores both the urgency of addressing a critical unmet need in mental health and Alto’s potential to bring a novel treatment to market more rapidly.
MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)—- $ANRO #FastTrack–Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS). There are currently no approved treatments for CIAS, a core feature of schizophrenia that
Source: Original Press Release
